ArticleMolecular pain
Znhit1 alleviates nitroglycerin-induced hyperalgesia in migraine mice via the inhibition of NOD-like receptor signaling pathway.
Article in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMigraine is a neurological disorder, affecting approximately 1.16 billion individuals globally. Zinc finger HIT-type containing 1 (Znhit1), a chromatin remodeler, has exhibited a neuroprotective role. This study aims to investigate the role of Znhit1 in migraine.
methodsA migraine mouse model was established by repeated intraperitoneal injection of nitroglycerin (NTG). The Znhit1 expression in trigeminal nucleus caudalis (TNC) was detected using reverse transcription quantitative polymerase chain reaction and western blot assays. Behavioral phenotype caused by central sensitization was assessed by Von Frey monofilaments and hot plate assays. Inflammatory response was evaluated through enzyme-linked immunosorbent assay and western blot analysis. Gene set enrichment analysis, western blot, cell counting kit-8 (CCK-8), and flow cytometry were utilized to explore potential molecular mechanisms in vitro.
resultsRepeated injection of NTG reduced Znhit1 expression in the TNC. Overexpression of Znhit1 alleviated hyperalgesia, upregulated 5-hydroxytryptamine (5-HT) level, and inhibited FBJ osteosarcoma oncogene (c-Fos) and calcitonin gene-related peptide (CGRP) expression. Moreover, overexpression of Znhit1 downregulated the expression of inflammatory markers [interleukin (IL)-6, IL-1β, tumor necrosis factor (TNF)-α, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS)] and inhibited the activation of NOD-like receptor protein 3 (NLRP3) inflammasome. CCK-8 assay found that cell viability was enhanced in lipopolysaccharide (LPS)-induced BV2 cells treated with Znhit1 overexpression, while silencing of Znhit1 resulted in decreased cell viability. In LPS-induced BV2 cells, silencing of Znhit1 enhanced inflammatory response, promoted cell apoptosis, and activated NLRP3 inflammasome, whereas MCC950, a specific inhibitor of NLRP3, reversed these effects induced by silencing of Znhit1.
conclusionOur results demonstrated that Znhit1 ameliorated hyperalgesia and inhibited inflammatory response by suppressing the activation of NLRP3 inflammasome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.